Her reached primary and secondary endpoints in the 3rd phase of the study of GnRH receptor antagonist relugolix

today, Myovant Sciencescompany(http:// announcedthat it has reached the primary and all critical secondary endpoints in the Phase 3 study HERO for the treatment of patients with advanced prostate cancerRelugolix is an oral GnRH receptor antagonist that binds and blocks GnRH receptors in the pituitary front already, reducing the release of progesterone-producing hormones (LH) and follicle stimulators (FSH), thereby reducing estrogen levels in women's ovaries and the production of male testosteroneMyovant Sciences is developing relugolix monodothel tablets for advanced prostate cancer and relugolix combination tablets for uterine fibroidsPreviously, the relugolix combination tablet scored positive results in the phase 3 clinicaltrial(http://for the treatment of uterine fibroidsA total of 1,100 prostate cancer patients participated in phase 3 clinical trials called HEROThe results showed that 96.7% of patients treated with relugolix continued to suppress their testosterone to anexoric level of 50 ng/dL, reaching the main end of the trialpatients in the treatment group significantly better than patients treated with acetate-lit-and-monochrelin in the active control group, reaching the critical secondary endpoint of the trial in terms of rapid suppression of testosterone and reducing prostate-specific antigen (PSA) levelsRelugolix consistently inhibited testosterone in patients for 48 weeks, reaching non-inferiority standards (non-inferiority) at 96.7% and 88.8%, respectively, compared with acetateThe pharmacodynamic results of thetrial showed that the patient satted no more short-term elevated testosterone levels after receiving relugolix treatment, and that the average testosterone level satrate returned to normal within 90 days of discontinuation